Cellectis (CLLS) Given Daily Coverage Optimism Rating of 0.14
Media coverage about Cellectis (NASDAQ:CLLS) has trended somewhat positive on Thursday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.8945788038008 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern’s scoring:
- Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy (finance.yahoo.com)
- Cellectis (CLLS) Presents At Jefferies 2017 London Healthcare Conference – Slideshow (seekingalpha.com)
- Zacks Investment Research Lowers Cellectis S.A. (CLLS) to Hold (americanbankingnews.com)
- ETFs with exposure to Cellectis SA : November 15, 2017 (finance.yahoo.com)
Several brokerages have recently issued reports on CLLS. SunTrust Banks, Inc. cut shares of Cellectis from a “buy” rating to a “hold” rating and decreased their target price for the company from $35.00 to $20.00 in a research report on Tuesday, September 5th. Zacks Investment Research cut shares of Cellectis from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. Nomura decreased their target price on shares of Cellectis from $49.00 to $43.00 and set a “buy” rating on the stock in a research report on Wednesday, September 6th. Jefferies Group LLC restated a “buy” rating and set a $47.00 target price on shares of Cellectis in a research report on Tuesday, September 26th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $40.00 target price (up from $33.00) on shares of Cellectis in a research report on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $39.50.
Shares of Cellectis (NASDAQ CLLS) opened at $24.30 on Thursday. Cellectis has a 1 year low of $16.09 and a 1 year high of $35.07.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.